ADAPT - A Patient Registry of the Real-world Use of Orenitram®
← catalyst calendarNCT03045029 · readout ≤ 223 d
Sponsored by United Therapeutics (industry) · UTHR — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
300estimated
Sites
41
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-07-18 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2017-02-07 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Arterial Hypertension
Intervention
- Drug: Oral treprostinil — also filed as Treprostinil diethanolamine, Treprostinil diolamine
Primary outcome
what the primary-completion date above is the date OFReal-world use and tolerability of Orenitram in new starts and prostacyclin transition patients
measured Baseline to Week 78
Permalink · UTHR's whole pipeline · Catalyst calendar · Every registered study · What changed